scPharmaceuticals Inc. (NASDAQ:SCPH) Short Interest Update

scPharmaceuticals Inc. (NASDAQ:SCPH) saw a significant decrease in short interest in September. As of September 15th, there was short interest totalling 4,250,000 shares, a decrease of 15.0% from the August 31st total of 5,000,000 shares. Based on an average daily volume of 264,000 shares, the short-interest ratio is currently 16.1 days.

scPharmaceuticals Trading Up 4.3 %

SCPH stock opened at $4.61 on Monday. The company has a quick ratio of 3.66, a current ratio of 4.84 and a debt-to-equity ratio of 4.32. scPharmaceuticals has a twelve month low of $3.24 and a twelve month high of $7.15. The company has a market cap of $230.64 million, a P/E ratio of -3.11 and a beta of 0.13. The business has a fifty day moving average of $4.95 and a 200-day moving average of $4.66.

scPharmaceuticals (NASDAQ:SCPH) last issued its earnings results on Wednesday, August 14th. The company reported ($0.44) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.44). scPharmaceuticals had a negative net margin of 252.18% and a negative return on equity of 201.84%. The company had revenue of $8.05 million for the quarter, compared to analyst estimates of $8.04 million. As a group, equities research analysts expect that scPharmaceuticals will post -1.34 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Thomasville National Bank grew its position in shares of scPharmaceuticals by 11.5% during the 1st quarter. Thomasville National Bank now owns 36,800 shares of the company’s stock worth $185,000 after buying an additional 3,800 shares during the period. Balanced Rock Investment Advisors LLC boosted its stake in scPharmaceuticals by 9.2% during the 1st quarter. Balanced Rock Investment Advisors LLC now owns 57,248 shares of the company’s stock worth $287,000 after acquiring an additional 4,827 shares during the last quarter. Perkins Capital Management Inc. acquired a new position in scPharmaceuticals during the first quarter valued at approximately $53,000. Bank of New York Mellon Corp increased its stake in scPharmaceuticals by 15.1% in the second quarter. Bank of New York Mellon Corp now owns 86,101 shares of the company’s stock valued at $375,000 after purchasing an additional 11,269 shares in the last quarter. Finally, Virtu Financial LLC acquired a new stake in scPharmaceuticals in the first quarter worth $90,000. 89.52% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $18.00 price target on shares of scPharmaceuticals in a report on Monday, August 19th.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.